The cognitive effects of esketamine: what do we know so far?

Introduction Esketamine is an S-enantiomer of ketamine approved by the EMA for treatment-resistant depression (TRD). As an NMDA receptor antagonist, its administration results in increase of glutamate release and AMPA receptor activation, supporting both rapid-onset and long-term antidepressant eff...

Descripción completa

Detalles Bibliográficos
Autores principales: M. Barbosa, R. Guedes
Formato: Artículo
Lenguaje:English
Publicado: Cambridge University Press 2022-06-01
Colección:European Psychiatry
Materias:
Acceso en línea:https://www.cambridge.org/core/product/identifier/S092493382201879X/type/journal_article